Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
REPRIEVE
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE
5 other identifiers
interventional
7,769
13 countries
137
Brief Summary
People with HIV are at risk for cardiovascular disease (CVD). This study evaluated the use of pitavastatin to reduce the risk of CVD in adults with HIV on antiretroviral therapy (ART). The REPRIEVE trial consisted of two parallel identical protocols:
- REPRIEVE (A5332) was funded by the NHLBI, with additional infrastructure support provided by the NIAID, and was conducted in U.S and select international sites (approximately 120 sites in 11 countries).
- REPRIEVE (EU5332) was co-sponsored by NEAT ID and MGH, and was conducted at 13 sites in Spain.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3 hiv
Started Mar 2015
Longer than P75 for phase_3 hiv
137 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 16, 2015
CompletedFirst Posted
Study publicly available on registry
January 22, 2015
CompletedStudy Start
First participant enrolled
March 26, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 21, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
August 21, 2023
CompletedResults Posted
Study results publicly available
October 15, 2024
CompletedSeptember 4, 2025
September 1, 2025
8.4 years
January 16, 2015
August 19, 2024
September 2, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence Rate of Major Adverse Cardiovascular Event (MACE)
MACE is a composite of cardiovascular (CV) death, myocardial infarction, hospitalization for unstable angina, stroke, transient ischemic attack (TIA), peripheral arterial ischemia, coronary, carotid or peripheral arterial revascularization, or death from an undetermined cause. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via cause-specific relative hazard (i.e. hazard ratio) of prescribed pitavastatin compared to placebo from Cox proportional hazards models, stratified by screening CD4 count and sex. Non-CV deaths (without preceding event of interest) were treated as competing events and censored. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Secondary Outcomes (34)
Incidence Rate of Cardiac Ischemia or Myocardial Infarction
From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Cerebrovascular Event (Stroke or TIA)
From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Peripheral Arterial Ischemia
From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Death From CV Causes
From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Death From CV or Undetermined Causes
From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
- +29 more secondary outcomes
Other Outcomes (2)
Incidence Rate of MACE by Sex
From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of MACE by Race
From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Study Arms (2)
Pitavastatin
EXPERIMENTALParticipants received pitavastatin once a day for the entire time they were in study follow-up.
Placebo
PLACEBO COMPARATORParticipants received placebo for pitavastatin once a day for the entire time they were in study follow-up.
Interventions
Eligibility Criteria
You may qualify if:
- Individual with HIV-1
- Combination antiretroviral therapy (ART) for at least 180 days prior to study entry
- CD4+ cell count greater than 100 cells/mm\^3
- Acceptable screening laboratories including:
- Fasting low-density lipoprotein (LDL) cholesterol as follows:
- If ASCVD risk score was less than 7.5%, LDL cholesterol must have been less than 190 mg/dL.
- If ASCVD risk score was greater than or equal to 7.5% and less than or equal to 10%, LDL must have been less than 160 mg/dL.
- If ASCVD risk score was greater than 10% and less than or equal to 15%, LDL must have been less than 130 mg/dL.
- Participants with LDL less than 70 mg/dL were eligible regardless of the 10-year ASCVD risk score, in line with the ACC/AHA 2013 Prevention Guidelines.
- Fasting triglycerides less than 500 mg/dL
- Hemoglobin greater than or equal to 8 g/dL for female participants and greater than or equal to 9 g/dL for male participants
- Glomerular filtration rate (GFR) greater than or equal to 60 mL/min/1.73m\^2 or creatinine clearance (CrCl) greater than or equal to 60 mL/min
- Alanine aminotransferase (ALT) less than or equal to 2.5 x the upper limit of normal (ULN)
- For persons with known chronic active hepatitis B or C, calculated fibrosis 4 score (FIB-4) must have been less than or equal to 3.25
- Ability and willingness of participant or legal representative to provide written informed consent
You may not qualify if:
- Clinical ASCVD, as defined by 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines, including a previous diagnosis of any of the following:
- Acute myocardial infarction (AMI)
- Acute coronary syndromes
- Stable or unstable angina
- Coronary or other arterial revascularization
- Stroke
- Transient ischemic attack (TIA)
- Peripheral arterial disease presumed to be of atherosclerotic origin
- Current diabetes mellitus with LDL greater than or equal to 70 mg/dL
- year ASCVD risk score estimated by Pooled Cohort Equations greater than 15%
- Active cancer within 12 months prior to study entry, except successfully treated non-melanomatous skin cancer and Kaposi sarcoma without visceral organ involvement
- Known decompensated cirrhosis
- History of myositis or myopathy with active disease in the 180 days prior to study entry
- Known untreated symptomatic thyroid disease
- History of allergy or severe adverse reaction to statins
- +8 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)lead
- National Heart, Lung, and Blood Institute (NHLBI)collaborator
- Kowa Pharmaceuticals America, Inc.collaborator
- Gilead Sciencescollaborator
- Massachusetts General Hospitalcollaborator
- NEAT ID Foundationcollaborator
Study Sites (137)
Alabama CRS*
Birmingham, Alabama, 35294, United States
University of Arizona CRS
Tucson, Arizona, 85724, United States
University of Southern California CRS*
Los Angeles, California, 90033-1079, United States
UCLA CARE Center CRS*
Los Angeles, California, 90035, United States
Mills Clinical Research CRS
Los Angeles, California, 90069, United States
VA West Los Angeles Medical Center CRS
Los Angeles, California, 90073, United States
Los Angeles LGBT Center CRS
Los Angeles, California, 90232, United States
Eisenhower Health Center at Rimrock CRS
Palm Springs, California, 92264, United States
Stanford AIDS Clinical Trials Unit CRS
Palo Alto, California, 94304-5350, United States
UCSD Antiviral Research Center CRS*
San Diego, California, 92103, United States
Ucsf Hiv/Aids Crs*
San Francisco, California, 94110, United States
Harbor-UCLA CRS*
Torrance, California, 90502, United States
University of Colorado Hospital CRS*
Aurora, Colorado, 80045, United States
Denver Public Health CRS
Denver, Colorado, 80204, United States
Yale University CRS
New Haven, Connecticut, 06510, United States
VA Connecticut Healthcare System CRS
West Haven, Connecticut, 06516, United States
Whitman-Walker Health CRS
Washington D.C., District of Columbia, 20005, United States
Georgetown University CRS (GU CRS)
Washington D.C., District of Columbia, 20007, United States
Capital Medical Associates, PC CRS
Washington D.C., District of Columbia, 20036, United States
Infectious Diseases Clinic, Washington DC Veterans Affairs Medical Center CRS
Washington D.C., District of Columbia, 20422, United States
Malcom Randall VA Medical Center CRS
Gainesville, Florida, 32610, United States
AHF-The Kinder Medical Group CRS
Miami, Florida, 33133, United States
The University of Miami AIDS Clinical Research Unit (ACRU) CRS
Miami, Florida, 33136, United States
University of Miami Infectious Disease Research Unit at Jackson Memorial Hospital CRS
Miami, Florida, 33136, United States
AHF - South Beach CRS
Miami, Florida, 33140, United States
Orlando Immunology Center CRS
Orlando, Florida, 32803, United States
Community AIDS Network/Comprehensive Care Clinic CRS
Sarasota, Florida, 34237, United States
Florida Department of Health - Hillsborough County
Tampa, Florida, 33602, United States
AIDS Research and Treatment Center of the Treasure Coast CRS
Vero Beach, Florida, 32960, United States
The Ponce de Leon Center CRS
Atlanta, Georgia, 30308-2012, United States
Augusta University Research Institute, Inc. CRS
Augusta, Georgia, 30912, United States
Northwestern University CRS*
Chicago, Illinois, 60611, United States
Rush University CRS*
Chicago, Illinois, 60612, United States
UIC Project WISH CRS
Chicago, Illinois, 60612, United States
Indiana University Infectious Diseases Research CRS
Indianapolis, Indiana, 46202, United States
Department of Internal Medicine, University of Iowa Hospitals & Clinics CRS
Iowa City, Iowa, 52242, United States
Bluegrass Care Clinic/University of Kentucky Research Foundation CRS
Lexington, Kentucky, 40536, United States
550 Clinic -University of Louisville CRS
Louisville, Kentucky, 40202, United States
Tulane - Louisiana Community AIDS Research Program (T-LaCARP) CRS
New Orleans, Louisiana, 70112, United States
Johns Hopkins University CRS*
Baltimore, Maryland, 21205, United States
Tufts Medical Center CRS
Boston, Massachusetts, 02111, United States
Massachusetts General Hospital CRS (MGH CRS)*
Boston, Massachusetts, 02114, United States
Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS*
Boston, Massachusetts, 02115, United States
Boston Medical Center CRS
Boston, Massachusetts, 02118, United States
Baystate Infectious Diseases Clinical Research CRS
Springfield, Massachusetts, 01199, United States
Henry Ford Hosp. CRS
Detroit, Michigan, 48202, United States
St. John Newland Medical Associates CRS
Southfield, Michigan, 48075, United States
Abbott Northwestern Hospital CRS
Minneapolis, Minnesota, 55407, United States
University of Mississippi Medical Center CRS
Jackson, Mississippi, 39213, United States
Washington University Therapeutics (WT) CRS*
St Louis, Missouri, 63110-1010, United States
Specialty Care Center CRS
Omaha, Nebraska, 68106, United States
Cooper Univ. Hosp. CRS
Camden, New Jersey, 08103, United States
New Jersey Medical School Clinical Research Center CRS*
Newark, New Jersey, 07103, United States
Mount Sinai Beth Israel CRS*
New York, New York, 10003, United States
VA New York Harbor Healthcare System (NYHHS), NY Campus CRS
New York, New York, 10010, United States
Weill Cornell Chelsea CRS*
New York, New York, 10010, United States
Mount Sinai Downtown CRS*
New York, New York, 10011, United States
Mount Sinai West Samuels CRS*
New York, New York, 10019, United States
Mount Sinai St. Luke's Morningside CRS*
New York, New York, 10025, United States
Infectious Disease Clinical and Translational Research Center (CTRC) CRS
New York, New York, 10029, United States
Columbia P&S CRS*
New York, New York, 10032-3732, United States
Weill Cornell Uptown CRS*
New York, New York, 10065, United States
University of Rochester Adult HIV Therapeutic Strategies Network CRS*
Rochester, New York, 14642, United States
James J Peters VA Medical Center CRS
The Bronx, New York, 10468, United States
Chapel Hill CRS*
Chapel Hill, North Carolina, 27599, United States
Duke University Medical Center CRS
Durham, North Carolina, 27710, United States
Greensboro CRS*
Greensboro, North Carolina, 27401, United States
Wake Forest Baptist Medical Center CRS
Winston-Salem, North Carolina, 27157, United States
Cincinnati Clinical Research Site*
Cincinnati, Ohio, 45219, United States
Case Clinical Research Site*
Cleveland, Ohio, 44106, United States
Ohio State University CRS*
Columbus, Ohio, 43210, United States
University of Toledo Medical Center CRS
Toledo, Ohio, 43614, United States
Oklahoma State University Center for Health Sciences CRS
Tulsa, Oklahoma, 74127, United States
Division of Infectious Diseases Clinical Research Center- Drexel University CRS
Philadelphia, Pennsylvania, 19102, United States
Penn Therapeutics, CRS*
Philadelphia, Pennsylvania, 19104, United States
Center of Translational AIDS Research, Lewis Katz School of Medicine at Temple University CRS
Philadelphia, Pennsylvania, 19140, United States
Positive Health Clinic CRS
Pittsburgh, Pennsylvania, 15212, United States
University of Pittsburgh CRS*
Pittsburgh, Pennsylvania, 15213, United States
The Miriam Hospital Clinical Research Site (TMH CRS) CRS*
Providence, Rhode Island, 02906, United States
Medical University of South Carolina: Division of Infectious Diseases CRS
Charleston, South Carolina, 29425, United States
Prisma Health CRS
Columbia, South Carolina, 29209, United States
Vanderbilt Therapeutics (VT) CRS*
Nashville, Tennessee, 37204, United States
Trinity Health and Wellness Center CRS
Dallas, Texas, 75208, United States
Dallas VA Medical Center CRS
Dallas, Texas, 75216, United States
UT Southwestern HIV/ID Clinical Trials Unit CRS
Dallas, Texas, 75235-9173, United States
Houston AIDS Research Team CRS*
Houston, Texas, 77030, United States
Michael E. DeBakey VAMC REPRIEVE CRS
Houston, Texas, 77030, United States
Inova Heart and Vascular Institute CRS
Falls Church, Virginia, 22042, United States
Virginia Commonwealth University CRS
Richmond, Virginia, 23298, United States
University of Washington AIDS CRS*
Seattle, Washington, 98104-9929, United States
Medical College of Wisconsin, Inc. CRS
Milwaukee, Wisconsin, 53226, United States
Gaborone CRS
Gaborone, South-East District, Botswana
Tropical Medicine Foundation Dr. Heitor Vieira Dourado CRS
Manaus, Amazonas, 69040000, Brazil
School of Medicine, Federal University of Minas Gerais CRS
Belo Horizonte, Minas Gerais, 30130-100, Brazil
HGNI HIV Family Care Clinic - HHFCC CRS
Nova Iguaçu, Rio de Janeiro, 26030-380, Brazil
Hospital Nossa Senhora da Conceicao CRS
Porto Alegre, Rio Grande do Sul, 91350-200, Brazil
Centro de Referencia e Treinamento DST/AIDS CRS
SĂ£o Paulo, SĂ£o Paulo, 04121-000, Brazil
Projeto Praça Onze Pesquisa em SaĂºde CRS
Rio de Janeiro, 20020-000, Brazil
Hospital Federal dos Servidores do Estado CRS
Rio de Janeiro, 20221-903, Brazil
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
Rio de Janeiro, 21040-360, Brazil
Instituto de Infectologia Emilio Ribas CRS
SĂ£o Paulo, 01246-900, Brazil
Centro de Pesquisas ClĂnicas IC-HCFMUSP CRS
SĂ£o Paulo, 05403-010, Brazil
Vancouver ID Research & Care Centre Society CRS
Vancouver, British Columbia, V6Z 2C7, Canada
Hamilton Health Sciences - Special Immunology Services Clinic CRS
Hamilton, Ontario, L8S 1A4, Canada
Maple Leaf Research CRS
Toronto, Ontario, M5G 1K2, Canada
Toronto General Hospital CRS
Toronto, Ontario, M5G 2N2, Canada
Chronic Viral Illness Service CRS
Montreal, Quebec, H4A 3J1, Canada
Centre hospitalier de l'Université Laval CRS
Québec, Quebec, G1V 4G2, Canada
GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS
Port-au-Prince, HT-6110, Haiti
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS
Port-au-Prince, HT-6110, Haiti
Byramjee Jeejeebhoy Medical College (BJMC) CRS
Pune, Maharashtra, 411001, India
Chennai Antiviral Research and Treatment (CART) CRS
Chennai, Tamil Nadu, 600113, India
Barranco CRS
Lima, 15063, Peru
San Miguel CRS
Lima, 32 - 15088, Peru
Puerto Rico AIDS Clinical Trials Unit CRS*
San Juan, PR, 00935, Puerto Rico
Soweto ACTG CRS
Johannesburg, Gauteng, 1862, South Africa
Wits Helen Joseph Hospital CRS (Wits HJH CRS)
Johannesburg, Gauteng, 2092, South Africa
Durban International Clinical Research Site CRS
Durban, KwaZulu-Natal, 4052, South Africa
University of Cape Town Lung Institute (UCTLI) CRS
Cape Town, Western Cape, 7700, South Africa
Famcru Crs
Tygerberg, Western Cape, 7505, South Africa
Hospital General Universitario de Alicante
Alicante, 03010, Spain
Hospital Germans Trias i Pujol
Badalona, 080916, Spain
Hospital Universitario Valle d'Hebron
Barcelona, 08003, Spain
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
Hospital Universitario de Bellvitge
Barcelona, 08907, Spain
Hospital Universitario de Basurto de Basurto
Bilbao, 48013, Spain
Hospital General Universitario De Elche
Elche, 03203, Spain
Hospital Gregorio Universitario Maranon
Madrid, 28007, Spain
Hospital Universitario Ramon y Cajal
Madrid, 28034, Spain
Hospital Universitario Clinico San Carlos
Madrid, 28040, Spain
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
Hospital Universitario La Paz
Madrid, 28046, Spain
Hospital Universitario Virgen de la Victoria
MĂ¡laga, 29010, Spain
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS
Bangkok, 10330, Thailand
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS
Chiang Mai, 50200, Thailand
Joint Clinical Research Centre (JCRC)/Kampala Clinical Research Site
Kampala, Uganda
Milton Park CRS
Harare, Zimbabwe
Related Publications (57)
Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PWF. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2935-2959. doi: 10.1016/j.jacc.2013.11.005. Epub 2013 Nov 12. No abstract available.
PMID: 24239921BACKGROUNDZanni MV, Fitch K, Rivard C, Sanchez L, Douglas PS, Grinspoon S, Smeaton L, Currier JS, Looby SE. Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial. HIV Clin Trials. 2017 Mar;18(2):83-91. doi: 10.1080/15284336.2017.1297551.
PMID: 28277924RESULTGrinspoon SK, Fitch KV, Overton ET, Fichtenbaum CJ, Zanni MV, Aberg JA, Malvestutto C, Lu MT, Currier JS, Sponseller CA, Waclawiw M, Alston-Smith B, Cooper-Arnold K, Klingman KL, Desvigne-Nickens P, Hoffmann U, Ribaudo HJ, Douglas PS; REPRIEVE Investigators. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Am Heart J. 2019 Jun;212:23-35. doi: 10.1016/j.ahj.2018.12.016. Epub 2019 Mar 4.
PMID: 30928825RESULTHoffmann U, Lu MT, Olalere D, Adami EC, Osborne MT, Ivanov A, Aluru JS, Lee S, Arifovic N, Overton ET, Fichtenbaum CJ, Aberg JA, Alston-Smith B, Klingman KL, Waclawiw M, Burdo TH, Williams KC, Zanni MV, Desvigne-Nickens P, Cooper-Arnold K, Fitch KV, Ribaudo H, Douglas PS, Grinspoon SK; REPRIEVE Investigators. Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. Am Heart J. 2019 Jun;212:1-12. doi: 10.1016/j.ahj.2019.02.011. Epub 2019 Mar 4.
PMID: 30928823RESULTGrinspoon SK, Douglas PS, Hoffmann U, Ribaudo HJ. Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators. J Infect Dis. 2020 Jul 9;222(Suppl 1):S1-S7. doi: 10.1093/infdis/jiaa098.
PMID: 32645161RESULTFitch KV, Kileel EM, Looby SE, Zanni MV, Sanchez LR, Fichtenbaum CJ, Overton ET, Malvestutto C, Aberg JA, Klingman KL, Alston-Smith B, Lavelle J, Rancourt A, Badal-Faesen S, Cardoso SW, Avihingsanon A, Patil S, Sponseller CA, Melbourne K, Ribaudo HJ, Cooper-Arnold K, Desvigne-Nickens P, Hoffmann U, Douglas PS, Grinspoon SK; REPRIEVE Investigators. Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination. HIV Res Clin Pract. 2020 Feb;21(1):11-23. doi: 10.1080/25787489.2020.1733794. Epub 2020 Mar 11.
PMID: 32160827RESULTOverton ET, Kantor A, Fitch KV, Muntner P, Supparatpinyo K, Mosepele M, Mohapi L, Cardoso SW, Patil S, de Lacerda MVG, McComsey G, Aberg JA, Douglas PS, Grinspoon SK, Ribaudo H, Wyatt CM. An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus. J Infect Dis. 2020 Jul 9;222(Suppl 1):S41-S51. doi: 10.1093/infdis/jiaa222.
PMID: 32645164RESULTFichtenbaum CJ, Ribaudo HJ, Leon-Cruz J, Overton ET, Zanni MV, Malvestutto CD, Aberg JA, Kileel EM, Fitch KV, Van Schalkwyk M, Kumarasamy N, Martinez E, Santos BR, Joseph Y, Lo J, Siminski S, Melbourne K, Sponseller CA, Desvigne-Nickens P, Bloomfield GS, Currier JS, Hoffmann U, Douglas PS, Grinspoon SK; REPRIEVE Investigators. Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. J Infect Dis. 2020 Jul 9;222(Suppl 1):S8-S19. doi: 10.1093/infdis/jiaa259.
PMID: 32645162RESULTSmeaton LM, Kileel EM, Grinsztejn B, Gardner EM, Starr K, Murry ML, Desvigne-Nickens P, Alston-Smith B, Waclawiw MA, Cooper-Arnold K, Madruga JV, Sangle S, Fitch KV, Zanni MV, Douglas PS, Ribaudo HJ, Grinspoon SK, Klingman KL. Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum. J Infect Dis. 2020 Jul 9;222(Suppl 1):S31-S40. doi: 10.1093/infdis/jiaa213.
PMID: 32645160RESULTZanni MV, Currier JS, Kantor A, Smeaton L, Rivard C, Taron J, Burdo TH, Badal-Faesen S, Lalloo UG, Pinto JA, Samaneka W, Valencia J, Klingman K, Allston-Smith B, Cooper-Arnold K, Desvigne-Nickens P, Lu MT, Fitch KV, Hoffman U, Grinspoon SK, Douglas PS, Looby SE. Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial. J Infect Dis. 2020 Jul 9;222(Suppl 1):S20-S30. doi: 10.1093/infdis/jiaa214.
PMID: 32645159RESULTNeilan TG, Nguyen KL, Zaha VG, Chew KW, Morrison L, Ntusi NAB, Toribio M, Awadalla M, Drobni ZD, Nelson MD, Burdo TH, Van Schalkwyk M, Sax PE, Skiest DJ, Tashima K, Landovitz RJ, Daar E, Wurcel AG, Robbins GK, Bolan RK, Fitch KV, Currier JS, Bloomfield GS, Desvigne-Nickens P, Douglas PS, Hoffmann U, Grinspoon SK, Ribaudo H, Dawson R, Goetz MB, Jain MK, Warner A, Szczepaniak LS, Zanni MV. Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. J Infect Dis. 2020 Jul 9;222(Suppl 1):S63-S69. doi: 10.1093/infdis/jiaa245.
PMID: 32645158RESULTDouglas PS, Umbleja T, Bloomfield GS, Fichtenbaum CJ, Zanni MV, Overton ET, Fitch KV, Kileel EM, Aberg JA, Currier J, Sponseller CA, Melbourne K, Avihingsanon A, Bustorff F, Estrada V, Ruxrungtham K, Saumoy M, Navar AM, Hoffmann U, Ribaudo HJ, Grinspoon S. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. Clin Infect Dis. 2021 Dec 6;73(11):2009-2022. doi: 10.1093/cid/ciab552.
PMID: 34134131RESULTHoffmann U, Lu MT, Foldyna B, Zanni MV, Karady J, Taron J, Zhai BK, Burdo T, Fitch KV, Kileel EM, Williams K, Fichtenbaum CJ, Overton ET, Malvestutto C, Aberg J, Currier J, Sponseller CA, Melbourne K, Floris-Moore M, Van Dam C, Keefer MC, Koletar SL, Douglas PS, Ribaudo H, Mayrhofer T, Grinspoon SK; REPRIEVE trial. Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. JAMA Netw Open. 2021 Jun 1;4(6):e2114923. doi: 10.1001/jamanetworkopen.2021.14923.
PMID: 34185068RESULTKileel EM, Lo J, Malvestutto C, Fitch KV, Zanni MV, Fichtenbaum CJ, Overton ET, Okeke NL, Kumar P, Joao E, Aberg JA, Martinez E, Currier JS, Douglas PS, Ribaudo HJ, Grinspoon SK. Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. Open Forum Infect Dis. 2021 Nov 20;8(12):ofab537. doi: 10.1093/ofid/ofab537. eCollection 2021 Dec.
PMID: 34888395RESULTFulda ES, Fitch KV, Overton ET, Zanni MV, Aberg JA, Currier JS, Lu MT, Malvestutto C, Fichtenbaum CJ, Martinez E, Umbleja T, Douglas PS, Ribaudo HJ, Grinspoon SK. COVID-19 Vaccination Rates in a Global HIV Cohort. J Infect Dis. 2022 Feb 15;225(4):603-607. doi: 10.1093/infdis/jiab575.
PMID: 34794178RESULTBloomfield GS, Weir IR, Ribaudo HJ, Fitch KV, Fichtenbaum CJ, Moran LE, Bedimo R, de Filippi C, Morse CG, Piccini J, Zanni MV, Lu MT, Hoffmann U, Grinspoon SK, Douglas PS. Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). J Acquir Immune Defic Syndr. 2022 Mar 1;89(3):349-359. doi: 10.1097/QAI.0000000000002877.
PMID: 35147583RESULTErlandson KM, Fitch KV, McCallum SA, Ribaudo HJ, Overton ET, Zanni MV, Bloomfield GS, Brown TT, Fichtenbaum CJ, Bares S, Aberg JA, Douglas PS, Fulda ES, Santana-Bagur JL, Castro JG, Moran LE, Mave V, Supparatpinyo K, Ponatshego PL, Schechter M, Grinspoon SK. Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk. Clin Infect Dis. 2022 Sep 30;75(7):1154-1163. doi: 10.1093/cid/ciac098.
PMID: 35165682RESULTLooby SE, Kantor A, Burdo TH, Currier JS, Fichtenbaum CJ, Overton ET, Aberg JA, Malvestutto CD, Bloomfield GS, Erlandson KM, Cespedes M, Kallas EG, Masia M, Thornton AC, Smith MD, Flynn JM, Kileel EM, Fulda E, Fitch KV, Lu MT, Douglas PS, Grinspoon SK, Ribaudo HJ, Zanni MV. Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy. Clin Infect Dis. 2022 Oct 12;75(8):1324-1333. doi: 10.1093/cid/ciac166.
PMID: 35235653RESULTOverton ET, Weir IR, Zanni MV, Fischinger S, MacArthur RD, Aberg JA, Fitch KV, Frank M, Albrecht H, Goodenough E, Rhame FS, Fichtenbaum CJ, Bloomfield GS, Malvestutto C, Supparatpinyo K, McCallum S, Douglas PS, Alter G, Ribaudo H, Grinspoon SK. Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV. J Acquir Immune Defic Syndr. 2022 Aug 1;90(4):377-381. doi: 10.1097/QAI.0000000000003000.
PMID: 35413022RESULTFitch KV, McCallum SA, Erlandson KM, Overton ET, Zanni MV, Fichtenbaum C, Aberg JA, Fulda ES, Kileel EM, Moran LE, Bloomfield GS, Novak RM, Perez-Frontera S, Abrams-Downey A, Pierone G Jr, Kumarasamy N, Ruxrungtham K, Mngqibisa R, Douglas PS, Ribaudo HJ, Grinspoon SK. Diet in a global cohort of adults with HIV at low-to-moderate traditional cardiovascular disease risk. AIDS. 2022 Nov 15;36(14):1997-2003. doi: 10.1097/QAD.0000000000003344. Epub 2022 Jul 27.
PMID: 35876637RESULTKolossvary M, deFilippi C, Lu MT, Zanni MV, Fulda ES, Foldyna B, Ribaudo H, Mayrhofer T, Collier AC, Bloomfield GS, Fichtenbaum C, Overton ET, Aberg JA, Currier J, Fitch KV, Douglas PS, Grinspoon SK. Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy. J Infect Dis. 2022 Nov 11;226(10):1809-1822. doi: 10.1093/infdis/jiac196.
PMID: 35535576RESULTZanni MV, Foldyna B, McCallum S, Burdo TH, Looby SE, Fitch KV, Fulda ES, Autissier P, Bloomfield GS, Malvestutto CD, Fichtenbaum CJ, Overton ET, Aberg JA, Erlandson KM, Campbell TB, Ellsworth GB, Sheth AN, Taiwo B, Currier JS, Hoffmann U, Lu MT, Douglas PS, Ribaudo HJ, Grinspoon SK. Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States. Clin Infect Dis. 2023 Jan 13;76(2):323-334. doi: 10.1093/cid/ciac767.
PMID: 36101518RESULTSchnittman SR, Lu MT, Mayrhofer T, Burdo TH, Fitch KV, McCallum S, Fulda ES, Zanni MV, Foldyna B, Malvestutto C, Fichtenbaum CJ, Aberg JA, Bloomfield GS, Overton ET, Currier J, Tebas P, Sha BE, Ribaudo HJ, Flynn JM, Douglas PS, Erlandson KM, Grinspoon SK. Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2023 Feb 8;76(3):e613-e621. doi: 10.1093/cid/ciac662.
PMID: 35975297RESULTDouglas PS, McCallum S, Lu MT, Umbleja T, Fitch KV, Foldyna B, Zanni MV, Fulda ES, Bloomfield GS, Fichtenbaum CJ, Overton ET, Aberg JA, Malvestutto CD, Burdo TH, Arduino RC, Ho KS, Yin MT, Ribaudo HJ, Grinspoon SK. Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIV. AIDS. 2023 Mar 1;37(3):423-434. doi: 10.1097/QAD.0000000000003418. Epub 2022 Nov 18.
PMID: 36525544RESULTFulda ES, Fichtenbaum CJ, Kileel EM, Zanni MV, Aberg JA, Malvestutto C, Cardoso SW, Berzins B, Lira R, Harden R, Robbins G, Martinez M, Nieves SD, McCallum S, Cruz JL, Umbleja T, Sprenger H, Giguel F, Bone F, Wood K, Byroads M, Paradis K, Lu MT, Douglas PS, Ribaudo HJ, Grinspoon SK, Fitch KV; REPRIEVE Investigators. The importance of methods for site performance evaluation in REPRIEVE, a longitudinal, global, multicenter trial. Contemp Clin Trials. 2023 Jan;124:107035. doi: 10.1016/j.cct.2022.107035. Epub 2022 Nov 30.
PMID: 36462699RESULTSchnittman SR, Jung W, Fitch KV, Zanni MV, McCallum S, Lee JS, Shin S, Davis BJ, Fulda ES, Diggs MR, Giguel F, Chinchay R, Sheth AN, Fichtenbaum CJ, Malvestutto C, Aberg JA, Currier J, Lauffenburger DA, Douglas PS, Ribaudo HJ, Alter G, Grinspoon SK. Effect of host factors and COVID-19 infection on the humoral immune repertoire in treated HIV. JCI Insight. 2023 Mar 8;8(5):e166848. doi: 10.1172/jci.insight.166848.
PMID: 36805331RESULTKileel EM, Malvestutto CD, Lo J, Fitch KV, Fichtenbaum CJ, Aberg JA, Zanni MV, Martinez E, Okeke NL, Kumar P, Joao E, Bares SH, Berrner D, Smieja M, Roa JC, McCallum S, Douglas PS, Ribaudo HJ, Grinspoon SK. Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE). Clin Infect Dis. 2023 Jun 8;76(11):2010-2013. doi: 10.1093/cid/ciad107.
PMID: 36825498RESULTSchnittman SR, Kitch DW, Swartz TH, Burdo TH, Fitch KV, McCallum S, Flynn JM, Fulda ES, Diggs MR, Stapleton JT, Casado JL, Taron J, Currier JS, Zanni MV, Malvestutto C, Fichtenbaum CJ, Aberg JA, Ribaudo HJ, Lu MT, Douglas PS, Grinspoon SK. Coronary Artery Plaque Composition and Severity Relate to the Inflammasome in People With Treated Human Immunodeficiency Virus. Open Forum Infect Dis. 2023 Mar 1;10(3):ofad106. doi: 10.1093/ofid/ofad106. eCollection 2023 Mar.
PMID: 36998633RESULTKolossvary M, deFilippi C, McCallum S, Fitch KV, Diggs MR, Fulda ES, Ribaudo HJ, Fichtenbaum CJ, Aberg JA, Malvestutto CD, Currier JS, Casado JL, Gutierrez F, Sereti I, Douglas PS, Zanni MV, Grinspoon SK. Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV. EBioMedicine. 2023 Apr;90:104538. doi: 10.1016/j.ebiom.2023.104538. Epub 2023 Mar 24.
PMID: 36966617RESULTFoldyna B, Mayrhofer T, Zanni MV, Lyass A, Barve R, Karady J, McCallum S, Burdo TH, Fitch KV, Paradis K, Fulda ES, Diggs MR, Bloomfield GS, Malvestutto CD, Fichtenbaum CJ, Aberg JA, Currier JS, Ribaudo HJ, Hoffmann U, Lu MT, Douglas PS, Grinspoon SK. Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People With HIV in the REPRIEVE Cohort. Clin Infect Dis. 2023 Dec 15;77(12):1676-1686. doi: 10.1093/cid/ciad419.
PMID: 37439633RESULTGrinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, Overton ET, Malvestutto CD, Bloomfield GS, Currier JS, Martinez E, Roa JC, Diggs MR, Fulda ES, Paradis K, Wiviott SD, Foldyna B, Looby SE, Desvigne-Nickens P, Alston-Smith B, Leon-Cruz J, McCallum S, Hoffmann U, Lu MT, Ribaudo HJ, Douglas PS; REPRIEVE Investigators. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection. N Engl J Med. 2023 Aug 24;389(8):687-699. doi: 10.1056/NEJMoa2304146. Epub 2023 Jul 23.
PMID: 37486775RESULTLake JE, Taron J, Ribaudo HJ, Leon-Cruz J, Utay NS, Swaminathan S, Fitch KV, Kileel EM, Paradis K, Fulda ES, Ho KS, Luetkemeyer AF, Johnston CD, Zanni MV, Douglas PS, Grinspoon SK, Lu MT, Fichtenbaum CJ; REPRIEVE Trial Investigators. Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV. AIDS. 2023 Nov 15;37(14):2149-2159. doi: 10.1097/QAD.0000000000003671. Epub 2023 Jul 27.
PMID: 37503623RESULTSchnittman SR, Kolossvary M, Beck-Engeser G, Fitch KV, Ambayec GC, Nance RM, Zanni MV, Diggs M, Chan F, McCallum S, Toribio M, Bamford L, Fichtenbaum CJ, Eron JJ, Jacobson JM, Mayer KH, Malvestutto C, Bloomfield GS, Moore RD, Umbleja T, Saag MS, Aberg JA, Currier JS, Delaney JAC, Martin JN, Lu MT, Douglas PS, Ribaudo HJ, Crane HM, Hunt PW, Grinspoon SK. Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency Virus. Open Forum Infect Dis. 2023 Sep 8;10(10):ofad467. doi: 10.1093/ofid/ofad467. eCollection 2023 Oct.
PMID: 37869406RESULTBhattacharya R, Uddin MM, Patel AP, Niroula A, Finneran P, Bernardo R, Fitch KV, Lu MT, Bloomfield GS, Malvestutto C, Aberg JA, Fichtenbaum CJ, Hornsby W, Ribaudo HJ, Libby P, Ebert BL, Zanni MV, Douglas PS, Grinspoon SK, Natarajan P. Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial. Blood Adv. 2024 Feb 27;8(4):959-967. doi: 10.1182/bloodadvances.2023011324.
PMID: 38197863RESULTLu MT, Ribaudo H, Foldyna B, Zanni MV, Mayrhofer T, Karady J, Taron J, Fitch KV, McCallum S, Burdo TH, Paradis K, Hedgire SS, Meyersohn NM, DeFilippi C, Malvestutto CD, Sturniolo A, Diggs M, Siminski S, Bloomfield GS, Alston-Smith B, Desvigne-Nickens P, Overton ET, Currier JS, Aberg JA, Fichtenbaum CJ, Hoffmann U, Douglas PS, Grinspoon SK; REPRIEVE Trial Writing Group. Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial. JAMA Cardiol. 2024 Apr 1;9(4):323-334. doi: 10.1001/jamacardio.2023.5661.
PMID: 38381407RESULTZou RS, Ruan Y, Truong B, Bhattacharya R, Lu MT, Karady J, Bernardo R, Finneran P, Hornsby W, Fitch KV, Ribaudo HJ, Zanni MV, Douglas PS, Grinspoon SK, Patel AP, Natarajan P. Polygenic Scores and Preclinical Cardiovascular Disease in Individuals With HIV: Insights From the REPRIEVE Trial. J Am Heart Assoc. 2024 Apr 2;13(7):e033413. doi: 10.1161/JAHA.123.033413. Epub 2024 Mar 27.
PMID: 38533953RESULTGrinspoon SK, Ribaudo HJ, Douglas PS. Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV Infection. N Engl J Med. 2024 May 2;390(17):1626-1628. doi: 10.1056/NEJMc2400870. No abstract available.
PMID: 38692296RESULTFoldyna B, Hadzic I, Mayrhofer T, Karady J, Taron J, Kolossvary M, Raghu VK, McCallum S, Paradis K, Diggs MR, Chu SM, Lu AB, Somboonwit C, Bernardino JI, Dube MP, Sponseller CA, Zanni MV, Bloomfield GS, Malvestutto CD, Fichtenbaum CJ, Aberg JA, Currier JS, Ribaudo HJ, Douglas PS, Lu MT, Grinspoon SK. Statin Effects on Pericoronary Adipose Tissue Density in People With HIV: Insights From the REPRIEVE Trial. JACC Cardiovasc Imaging. 2025 Nov 24:S1936-878X(25)00594-7. doi: 10.1016/j.jcmg.2025.10.012. Online ahead of print.
PMID: 41324519DERIVEDDiggs MR, Chu SM, Fitch KV, Olefsky M, Watanabe MG, Erlandson KM, Lu AB, Bloomfield GS, Currier JS, Curran A, Eckard AR, Smith GHR, Sponseller CA, Fichtenbaum CJ, Malvestutto CD, Aberg JA, Foldyna B, Taron J, Karady J, Zanni MV, Douglas PS, Ribaudo HJ, Lu MT, Grinspoon SK. Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial. AIDS. 2025 Nov 10. doi: 10.1097/QAD.0000000000004401. Online ahead of print.
PMID: 41217428DERIVEDXue L, Bhattacharya R, Uddin MM, Nakao T, Zou R, Patel A, Haidermota S, Niroula A, Viscosi V, Postupaka D, Bhatnagar A, Finneran P, Bernardo R, Diggs MR, Fitch KV, Chu SM, McCallum S, Currier JS, Fichtenbaum CJ, Malvestutto CD, Aberg JA, Bloomfield GS, Ribaudo HJ, Zanni MV, Libby P, Hornsby W, Lu MT, Douglas PS, Grinspoon SK, Natarajan P. Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE Trial. Arterioscler Thromb Vasc Biol. 2026 Jan;46(1):168-177. doi: 10.1161/ATVBAHA.125.322896. Epub 2025 Nov 6.
PMID: 41195533DERIVEDGrinspoon SK, Zhao S, Martinez E, Fichtenbaum CJ, Chu SM, Diggs MR, Umbleja T, McCallum S, Fitch KV, Triant VA, Currier JS, Aberg JA, Malvestutto CD, Erlandson KM, Bloomfield GS, Lu MT, Douglas PS, Ribaudo HJ, Zanni MV. Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2. Clin Infect Dis. 2025 Sep 26:ciaf542. doi: 10.1093/cid/ciaf542. Online ahead of print.
PMID: 41004413DERIVEDKolossvary M, Sereti I, Zanni MV, Fichtenbaum CJ, Aberg JA, Bloomfield GS, Malvestutto CD, Currier JS, Chu SM, Diggs MR, Lu AB, deFilippi C, Foldyna B, McCallum S, Sponseller CA, Lu MT, Douglas PS, Ribaudo HJ, Grinspoon SK. Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV. J Clin Invest. 2025 Sep 9;135(22):e196021. doi: 10.1172/JCI196021. eCollection 2025 Nov 17.
PMID: 40924496DERIVEDCorley MJ, Watanabe M, Pang APS, Dwaraka VB, Smith R, Samaneka W, Henn S, Munsiff S, Saumoy M, McCallum S, Fitch KV, Chu SM, Diggs MR, Aberg JA, Malvestutto CD, Fichtenbaum CJ, Currier JS, Zanni MV, Douglas PS, Lu MT, Landay AL, Erlandson KM, Ribaudo HJ, Grinspoon SK. Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial. Clin Infect Dis. 2025 Jun 18:ciaf247. doi: 10.1093/cid/ciaf247. Online ahead of print.
PMID: 40576558DERIVEDFichtenbaum CJ, Malvestutto CD, Watanabe MG, Davies Smith E, Ribaudo HJ, McCallum S, Fitch KV, Currier JS, Diggs MR, Chu SM, Aberg JA, Lu MT, Valencia J, Gomez-Ayerbe C, Brar I, Valdez Madruga J, Bloomfield GS, Douglas PS, Zanni MV, Grinspoon SK; REPRIEVE Investigators. Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis. Lancet HIV. 2025 Jul;12(7):e496-e505. doi: 10.1016/S2352-3018(25)00043-8. Epub 2025 Jun 4.
PMID: 40482662DERIVEDLu MT, Ribaudo HJ, McCallum S, Zanni MV, deFilippi C, Taron J, Karady J, Foldyna B, Paradis K, Chu SM, Diggs MR, Burdo TH, Currier JS, Bloomfield GS, Fichtenbaum CJ, Malvestutto CD, Aberg JA, Mayrhofer T, Douglas PS, Grinspoon SK; REPRIEVE Investigators. Coronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE Substudy. JACC Adv. 2025 Jun;4(6 Pt 1):101781. doi: 10.1016/j.jacadv.2025.101781. Epub 2025 May 14.
PMID: 40373520DERIVEDGrinspoon SK, Watanabe M, Ribaudo HJ, Bloomfield GS, Fichtenbaum CJ, Umbleja T, Chu SM, Fitch KV, Diggs MR, Zhao S, Looby SE, Currier JS, Aberg JA, Malvestutto CD, Erlandson KM, Martinez E, Asupoto O, Gupta SK, Lopez-Bernaldo de Quiros JC, Nixon D, Bedimo R, Lu MT, Douglas PS, Zanni MV. Factors Affecting Risk of Cardiovascular Disease (CVD) Events in a Global CVD Prevention Cohort of People With HIV. Clin Infect Dis. 2026 Feb 4;81(6):e548-e557. doi: 10.1093/cid/ciaf210.
PMID: 40281648DERIVEDDavies Smith E, Malvestutto C, Ribaudo HJ, Fichtenbaum CJ, Aberg JA, Watanabe M, Bloomfield GS, Currier JS, Chu SM, Fitch KV, Diggs MR, Bedimo R, Valencia J, Gomez-Ayerbe C, Brar I, Madruga JV, Lu MT, Douglas PS, Zanni MV, Grinspoon SK. Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort. Open Forum Infect Dis. 2025 Mar 21;12(4):ofaf177. doi: 10.1093/ofid/ofaf177. eCollection 2025 Apr.
PMID: 40207047DERIVEDDiggs MR, Umbleja T, McCallum S, Zanni MV, Chu SM, Fitch KV, Bloomfield GS, Currier JS, Martinez E, Castle PE, Awwad A, Jain MK, Bedimo R, Hendricks B, Narrea J, Estrada V, Pinto J, Aberg JA, Malvestutto CD, Fichtenbaum CJ, Lu MT, Ribaudo HJ, Douglas PS, Grinspoon SK. Statin effects on the incidence of major non-cardiovascular disease events among a global cohort of people with HIV: a randomised controlled trial. Lancet HIV. 2025 Apr;12(4):e261-e272. doi: 10.1016/S2352-3018(24)00345-X.
PMID: 40180472DERIVEDGrinspoon SK, Zanni MV, Triant VA, Kantor A, Umbleja T, Diggs MR, Chu SM, Fitch KV, Currier JS, Bloomfield GS, Casado JL, de la Pena M, Fantry LE, Gardner E, Aberg JA, Malvestutto CD, Fichtenbaum CJ, Lu MT, Ribaudo HJ, Douglas PS. Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE. Lancet HIV. 2025 Feb;12(2):e118-e129. doi: 10.1016/S2352-3018(24)00276-5. Epub 2025 Jan 17.
PMID: 39832519DERIVEDKolossvary M, Schnittman SR, Zanni MV, Fitch KV, Fichtenbaum CJ, Aberg JA, Bloomfield GS, Malvestutto CD, Currier J, Diggs MR, deFilippi C, Eckard AR, Curran A, Centinbas M, Sadreyev R, Foldyna B, Mayrhofer T, Karady J, Taron J, McCallum S, Lu MT, Ribaudo HJ, Douglas PS, Grinspoon SK. Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial. JAMA Cardiol. 2025 Mar 1;10(3):254-264. doi: 10.1001/jamacardio.2024.4115.
PMID: 39661372DERIVEDZanni MV, Umbleja T, Fichtenbaum CJ, Fitch KV, McCallum S, Aberg JA, Overton ET, Malvestutto CD, Bloomfield GS, Currier JS, Schnittman SR, Erlandson KM, Diggs MR, Foldyna B, Martinez E, Somboonwit C, Wang GP, Mushatt D, Connick E, Lu MT, Douglas PS, Ribaudo HJ, Grinspoon SK. Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among a Global Cohort of People With HIV. Open Forum Infect Dis. 2024 Oct 10;11(10):ofae574. doi: 10.1093/ofid/ofae574. eCollection 2024 Oct.
PMID: 39435321DERIVEDFitch KV, Zanni MV, Manne-Goehler J, Diggs MR, Gattu AK, Currier JS, Bloomfield GS, Hsiao CB, Gupta SK, Aberg JA, Malvestutto CD, Fichtenbaum CJ, Lu MT, Douglas PS, Ribaudo HJ, Grinspoon SK. Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention : A Randomized Trial. Ann Intern Med. 2024 Nov;177(11):1449-1461. doi: 10.7326/ANNALS-24-00944. Epub 2024 Oct 8.
PMID: 39374532DERIVEDdeFilippi C, McCallum S, Zanni MV, Fitch KV, Diggs MR, Bloomfield GS, Fichtenbaum CJ, Aberg JA, Malvestutto CD, Pinto-Martinez A, Stapleton A, Duggan J, Robbins GK, Taron J, Karady J, Foldyna B, Lu MT, Ribaudo HJ, Douglas PS, Grinspoon SK. Association of Cardiac Troponin T With Coronary Atherosclerosis in Asymptomatic Primary Prevention People With HIV. JACC Adv. 2024 Aug 16;3(9):101206. doi: 10.1016/j.jacadv.2024.101206. eCollection 2024 Sep.
PMID: 39253712DERIVEDErlandson KM, Umbleja T, Ribaudo HJ, Schrack JA, Overton ET, Fichtenbaum CJ, Fitch KV, Roa JC, Diggs MR, Wood K, Zanni MV, Bloomfield GS, Malvestutto C, Aberg JA, Rodriguez-Barradas MC, Morones RG, Breaux K, Douglas PS, Grinspoon SK, Brown TT. Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function. Clin Infect Dis. 2025 Feb 24;80(2):425-433. doi: 10.1093/cid/ciae422.
PMID: 39159048DERIVEDAbidi MZ, Umbleja T, Overton ET, Burdo T, Flynn JM, Lu MT, Taron J, Schnittman SR, Fitch KV, Zanni MV, Fichtenbaum CJ, Malvestutto C, Aberg JA, Fulda ES, Eckard AR, Manne-Goehler J, Tuan JJ, Ribaudo HJ, Douglas PS, Grinspoon SK, Brown TT, Erlandson KM. Cytomegalovirus IgG is Associated With Physical Function But Not Muscle Density in People With HIV. J Acquir Immune Defic Syndr. 2024 Apr 15;95(5):470-478. doi: 10.1097/QAI.0000000000003377.
PMID: 38180893DERIVEDErlandson KM, Umbleja T, Lu MT, Taron J, Ribaudo HJ, Overton ET, Presti RM, Haas DW, Sax PE, Yin MT, Zhai BK, Louis R, Upadhyay N, Eslami P, Douglas PS, Zanni MV, Fitch KV, Fulda ES, Fichtenbaum CJ, Malvestutto CD, Grinspoon SK, Brown TT. Associations of Muscle Density and Area With Coronary Artery Plaque and Physical Function. J Acquir Immune Defic Syndr. 2023 Oct 1;94(2):174-184. doi: 10.1097/QAI.0000000000003244.
PMID: 37368931DERIVEDUmbleja T, Brown TT, Overton ET, Ribaudo HJ, Schrack JA, Fitch KV, Douglas PS, Grinspoon SK, Henn S, Arduino RC, Rodriguez B, Benson CA, Erlandson KM. Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE. J Infect Dis. 2020 Jul 9;222(Suppl 1):S52-S62. doi: 10.1093/infdis/jiaa249.
PMID: 32645163DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- REPRIEVE Project Manager
- Organization
- REPRIEVE Clinical Coordinating Center
Study Officials
- STUDY CHAIR
Steven Grinspoon, MD
Harvard Medical School (HMS and HSDM)
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- LTE60
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- NIH
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 16, 2015
First Posted
January 22, 2015
Study Start
March 26, 2015
Primary Completion
August 21, 2023
Study Completion
August 21, 2023
Last Updated
September 4, 2025
Results First Posted
October 15, 2024
Record last verified: 2025-09